Back to search results
NCT07202403

Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies

Enrolling by Invitation
NAAges 18–75InterventionalPrevention
Atria Research and Global Health Institute (ARGHI)
~10 participants
Updated 2025-10-01 on ClinicalTrials.gov
What's tested:Spermidine

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and tolerability
Measured over Baseline to Day 112

Conditions

Aging
Longevity

Explore related trials

Aging

NCT07202403

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Atria Research and Global Health Institute

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 18 to 75
Patients without known significant organ dysfunction, based on standard blood tests within the last year

Exclusion

Patients taking any immunomodulatory medications that the investigator or treating physician believe may alter the immune response to the study agent (e.g. biologic antibodies, immunosuppressants)
Patients actively receiving any therapy that, in the determination of the investigator, may impact the effect of the study agent.
Patients who, in the opinion of the treating investigator, will not be able to follow treatment and defined follow-up
Pregnancy

What this trial measures

  • Safety and tolerabilityBaseline to Day 112

    Assessment of toxicity of therapeutic intervention. Toxicity will be assessed through adverse event monitoring conducted at clinic visits or by phone, with adverse events evaluated and graded using CTCAE v5.0.